The year-over-year increase in revenues was driven by higher Diabetes and Obesity Care sales as GLP-1 product sales ... with the industry’s 3.1% decline. Image Source: Zacks Investment Research ...

with disappointing data for phase 2 drug monlunabant in September and phase 3 GLP-1 and amylin combination cagrisema in December. Novo and Lilly are fighting for share in the global GLP-1 market ...

Hims & Hers’ decision to advertise at the Super Bowl represents an ambitious play for the brand as it positions itself in the ...

GLP-1 drugs are also engineered peptides, which are expensive to manufacture. Metsera has technologies and drug candidates intended ... the Nasdaq Friday under the stock symbol “MTSR.” ...